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Background
Previously, we identified a series of T-cell epitopes from
the major cat allergen Fel d1 and showed these were
safe and well-tolerated when administered to cat allergic
subjects. In the current study, we evaluated persistence
of the treatment effect (tolerance) one year after start of
dosing for two treatment regimens with the same cumu-
lative dose.
Methods
Subjects underwent Baseline Challenge in an Environmental
Exposure Chamber (EEC) on 4 consecutive days, consisting
of 3-hour allergen exposures (Fel d1 50.19±3.70 ng/m3).
Subjects scored four nasal and four ocular symptoms every
30 minutes each on a scale of 0-3. 202 subjects were rando-
mised to placebo, 8x3nmol Cat Peptide Antigen Desensiti-
sation (Cat-PAD) 2weeks(wk) apart or 4x6nmol Cat-PAD
4wk apart. Subjects re-attended the EEC for 4 consecutive
days, of 3-hours, 18-22wk after the start of treatment.
50-54wk after commencement of treatment subjects were
invited to participate in a blinded follow-on study without
further dosing. 89 subjects were enrolled and had a further
4 consecutive days, of 3-hours in the EEC.
Results
4x6nmol Cat-PAD showed a mean change in the Total
Rhinoconjunctivitis Symptom Score (TRSS) at the 50-54wk
EEC visit of -6.78±5.71 versus a change of -3.89±5.56 on
8x3nmol and -2.91±5.56 on placebo. The change in TRSS
score for 4x6nmol was statistically significantly different to
placebo (p=0.01) and 8x3nmol (p=0.03). For the 4x6nmol
regimen, the treatment effect at 50-54w trended higher
than that seen at 18-22wk (4x6nmol -5.41±5.80; placebo
-2.79±5.28). At the 50-54w EEC visit treatment with
4x6nmol Cat-PAD showed a mean change in Total Nasal
Symptom Score of -3.44±3.05 versus a change of -1.63±
2.95 on placebo (p=0.02) and a mean change in the Total
Ocular Symptom Score of -3.34±3.05 versus a change of
-1.28±2.92 on placebo (p=0.01).
Conclusions
Treatment with four injections of Cat-PAD showed a sub-
stantial reduction in patients’ overall TRSS, and the ocular
and nasal components of cat allergy symptom scores in
the EEC model that persisted one year after the start of
treatment. Four administrations of a 6nmol dose was
superior to eight administrations of a 3nmol dose and pla-
cebo. The treatment effect trended higher at one year than
at 18-22wk.
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